Rallybio to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, will participate in two investor conferences: the Jefferies London Healthcare Conference on November 15, 2022, at 8:35 a.m. GMT and the Evercore ISI 5th Annual HealthCONx Conference virtually on November 30, 2022, at 8:25 a.m. EST. Live webcasts will be available on Rallybio's website, with replays accessible for 30 days post-event.

Founded in January 2018, Rallybio focuses on therapies for severe and rare diseases.

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

• Jefferies London Healthcare Conference in London, United Kingdom on Tuesday, November 15, 2022, at 8:35 a.m. GMT (3:35 a.m. EST)
• Evercore ISI 5th Annual HealthCONx Conference being held virtually on Wednesday, November 30, 2022, at 8:25 a.m. EST.

Live webcasts of both fireside chats will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each event.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109006005/en/

Investors

Ami Bavishi

Head of Investor Relations and Corporate Communications

609-477-4536

abavishi@rallybio.com

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Media

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

Source: Rallybio Corporation

FAQ

What conferences will Rallybio Corporation (RLYB) participate in November 2022?

Rallybio Corporation will participate in the Jefferies London Healthcare Conference on November 15, 2022, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022.

What is the date and time of the Jefferies London Healthcare Conference for Rallybio (RLYB)?

The Jefferies London Healthcare Conference for Rallybio is scheduled for November 15, 2022, at 8:35 a.m. GMT.

Where can I watch the webcasts for Rallybio's investor conferences?

The webcasts for Rallybio's investor conferences will be available on their website under the Events and Presentations section.

When will the replay of the webcasts for Rallybio's conferences be available?

Replays of the webcasts will be accessible for 30 days following each event.

What is the focus of Rallybio Corporation's research and development?

Rallybio Corporation focuses on developing therapies for patients with severe and rare diseases.